Michael John Tomsicek Crispr Therapeutics Ag (CRSP) insider trading activity

Michael John Tomsicek is Chief Financial Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 1,891 shares of CRSP, which is worth approximately $95,306. The most recent transaction as insider was on Aug 06, 2021, when has been sold 25,000 shares (Common Shares) at a price of $138.84 per share, resulting in proceeds of $3,471,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.89K

0% 3M change

0% 12M change

Total Value Held $95,306

MICHAEL JOHN TOMSICEK Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 06 2021	SELL Open market or private sale	$3,471,000 $138.84 p/Share	25,000 Reduced 92.97%	1,891 Common Shares
Aug 06 2021	BUY Exercise of conversion of derivative security	$443,750 $17.75 p/Share	25,000 Added 48.18%	26,891 Common Shares
Mar 10 2021	SELL Payment of exercise price or tax liability	$167,851 $124.15 p/Share	1,352 Reduced 41.69%	1,891 Common Shares
Mar 10 2021	BUY Exercise of conversion of derivative security	-	2,833 Added 46.63%	3,243 Common Shares
Sep 01 2020	SELL Open market or private sale	$1,107,240 $92.27 p/Share	12,000 Reduced 96.7%	410 Common Shares
Sep 01 2020	BUY Exercise of conversion of derivative security	$213,000 $17.75 p/Share	12,000 Added 49.16%	12,410 Common Shares
Aug 03 2020	SELL Open market or private sale	$1,041,480 $86.79 p/Share	12,000 Reduced 96.7%	410 Common Shares
Aug 03 2020	BUY Exercise of conversion of derivative security	$213,000 $17.75 p/Share	12,000 Added 49.16%	12,410 Common Shares

Also insider at

MIST

Milestone Pharmaceuticals Inc. Healthcare

ACRV

Acrivon Therapeutics, Inc.

MJT